Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1167-1180

  Sero, Valeria ^a   Tavanti, Elisa ^a   Vella, Serena ^a   Hattinger, Claudia Maria ^a   Fanelli, Marilù ^a   Michelacci, Francesca ^a   Versteeg, Rogier ^b   Valsasina, Barbara ^c   Gudeman, Beth ^d   Picci, Piero ^a   Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NERVIANO MEDICAL SCIENCES   (Italy)

^d CBA Research Inc   (United States)

Author keywords

ABCB1; Drug resistance; NMS P937; Novel therapeutic strategies; Osteosarcoma; Polo like kinase 1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CBT 1; CISPLATIN; DOXORUBICIN; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NMS P 937; POLO LIKE KINASE 1; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NMS P937; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SMALL INTERFERING RNA;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; MIGRATION INHIBITION; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PLK1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEIN TRANSPORT; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL CYCLE; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; OSTEOSARCOMA; P-GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; QUINAZOLINES; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84927513102     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0158-6     Document Type: Article

References (36)

1. Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9(8):643-660. doi: 10.1038/nrd3184
2. de Carcer G, Manning G, Malumbres M (2011) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10(14):2255-2262
3. Weiss L, Efferth T (2012) Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol 1(1):38. doi: 10.1186/2162-3619-1-38
4. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3(5):641-646
5. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y (2005) Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65(7):2698-2704. doi: 10.1158/0008-5472.CAN-04-2131
6. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K (2004) Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96(11):862-872
7. Liu X, Lei M, Erikson RL (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26(6):2093-2108. doi: 10.1128/MCB.26.6.2093-2108.2006
8. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T (2009) Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 100(12):2268-2274. doi: 10.1111/j.1349-7006.2009.01310.x
9. Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z (2011) Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 22(5):444-453. doi: 10.1097/CAD.0b013e32834513f4
10. Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG (2011) BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 22(10):995-1001. doi: 10.1097/CAD.0b013e32834a16d4
11. Spaniol K, Boos J, Lanvers-Kaminsky C (2011) An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anticancer Drugs 22(6):531-542. doi: 10.1097/CAD.0b013e3283454526
12. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P, Scotlandi K (1999) Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80(4):581-588. doi: 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.0.CO;2-O
13. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49(1):40-51. doi: 10.1002/gcc.20717
14. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M (2008) Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68(16):6661-6668. doi: 10.1158/0008-5472.CAN-07-5840
15. Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P (2004) Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15(1):151-160
16. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G, Baldini N (1993) Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13(2):323-329
17. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Ora I, Speleman F, Caron HN, Versteeg R (2012) Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51(1):10-19. doi: 10.1002/gcc.20926
18. Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M (2013) Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 109(10):2607-2618. doi: 10.1038/bjc.2013.643
19. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M (2009) Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48(4):289-309. doi: 10.1002/gcc.20640
20. Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE (2012) A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 17(4):512. doi: 10.1634/theoncologist.2012-0080
21. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75(6):1302-1312. doi: 10.1016/j.bcp.2007.12.001
22. Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6(7):1075-1085. doi: 10.1586/14737140.6.7.1075
23. Dai X, Ma W, He X, Jha RK (2011) Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 17(8):RA177-190
24. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M (2010) Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15(4):615-634. doi: 10.1517/14728214.2010.505603
25. Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, Yang C, Mankin H, Hornicek FJ (2010) Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 293(2):220-229. doi: 10.1016/j.canlet.2010.01.014
26. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8(11):3024-3035. doi: 10.1158/1535-7163.MCT-09-0365
27. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21(10):2969-2974. doi: 10.1016/j.bmcl.2011.03.054
28. Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11(4):1006-1016. doi: 10.1158/1535-7163.MCT-11-0765
29. Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R (2013) The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One 8(3):e58424. doi: 10.1371/journal.pone.0058424
30. Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M (2007) Cell type - dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 6(12 Pt 1):3189-3197. doi: 10.1158/1535-7163.MCT-07-0048
31. Louwen F, Yuan J (2013) Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget 4(7):958-971
32. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 106(10):3964-3969. doi: 10.1073/pnas.0813333106
33. Tang N, Song WX, Luo J, Haydon RC, He TC (2008) Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466(9):2114-2130. doi: 10.1007/s11999-008-0335-z
34. Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 18(6):BR237-246
35. Zhang G, Zhang Z, Liu Z (2013) Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol 34(3):1887-1894. doi: 10.1007/s13277-013-0732-0
36. Zhang Z, Zhang G, Kong C (2013) High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 31(7):1222-1230. doi: 10.1016/j.urolonc.2011.11.028